The prognostic value of Stathmin-1, S100A2, and SYK proteins in ER-positive primary breast cancer patients treated with adjuvant tamoxifen monotherapy: an immunohistochemical study

2007 ◽  
Vol 110 (2) ◽  
pp. 317-326 ◽  
Author(s):  
Rastko Golouh ◽  
Tanja Cufer ◽  
Aleksander Sadikov ◽  
Petra Nussdorfer ◽  
Pernille Autzen Usher ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Primary Breast Cancer ◽  
Prognostic Value ◽  
Immunohistochemical Study ◽  
Adjuvant Tamoxifen ◽  
Breast Cancer Patients ◽  
Stathmin 1 ◽  
Er Positive

BENEFICIAL EFFECT OF ADJUVANT TAMOXIFEN THERAPY IN PRIMARY BREAST CANCER PATIENTS WITH HIGH OESTROGEN RECEPTOR VALUES

The Lancet ◽  
1985 ◽  
Vol 325 (8419) ◽  
pp. 16-19 ◽  
Author(s):  
Carsten Rose ◽  
KnudW. Andersen ◽  
HenningT. Mouridsen ◽  
SusanM. Thorpe ◽  
BoV. Pedersen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Beneficial Effect ◽  
Cancer Patients ◽  
Primary Breast Cancer ◽  
Oestrogen Receptor ◽  
Tamoxifen Therapy ◽  
Adjuvant Tamoxifen ◽  
Breast Cancer Patients ◽  
Adjuvant Tamoxifen Therapy

Prognostic value of serum Cytokeratin19-2G2 in primary breast cancer patients.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. e11091-e11091
Author(s):  
Xiaoming Xie ◽  
Yana Kong ◽  
Shuqin Dai ◽  
Wanli Liu ◽  
Weidong Wei
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Primary Breast Cancer ◽  
Prognostic Value ◽  
Lymph Node Involvement ◽  
High Serum ◽  
Breast Cancer Patients ◽  
Serum Samples ◽  
Node Involvement ◽  
Independent Indicator

e11091 Background: Cytokeratin19-2G2, one of cytokeratin19 fragments, has been considered as one of the most sensitive tumor markers. However, no previous studies reported of CK19-2G2 in breast cancer. The purpose of our study is to evaluate the prognostic value of CK19-2G2 in primary breast cancer patients. Methods: This study included 249 primary breast cancer patients with stage 0-III, 81 healthy controls and 21 breast benign disease patients. Serum samples were conserved before surgery. CK19-2G2, CEA and CA153 were measured by chemiluminescent assay and ER, PR, CerbB2 were assessed by Immunohistochemistry assay. Results: Serum CK19-2G2 levels in breast cancer patients were significantly higher than that in healthy and benign controls (P < 0.001). High serum CK19-2G2 levels (≥2 ng/mL) were associated with stage III (P < 0.001), tumor size (≥2cm) (P < 0.001), lymph node involvement (P < 0.001), negative estrogen receptor (P = 0.005) and progesterone receptor status (P = 0.001). Multivariate analysis revealed that high serum CK19-2G2 level was an independent factor for relapse (P = 0.029) and death (P = 0.040) in primary breast cancer patients. Conclusions: High serum CK19-2G2 levels maybe considered as an independent indicator for prognosis in primary breast cancer.

Clinical relevance of H-RAS, K-RAS and N-RAS in a large cohort of primary breast cancer patients

2018 ◽  
Author(s):  
M Banys-Paluchowski ◽  
K Milde-Langosch ◽  
T Fehm ◽  
I Witzel ◽  
L Oliveira-Ferrer ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Clinical Relevance ◽  
Primary Breast Cancer ◽  
Large Cohort ◽  
Breast Cancer Patients

scholarly journals Prospective comparison of the diagnostic accuracy of 18F-FDG PET/MRI, MRI, CT, and bone scintigraphy for the detection of bone metastases in the initial staging of primary breast cancer patients

2021 ◽  
Author(s):  
Nils Martin Bruckmann ◽  
Julian Kirchner ◽  
Lale Umutlu ◽  
Wolfgang Peter Fendler ◽  
Robert Seifert ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Metastases ◽  
Cancer Patients ◽  
Bone Scintigraphy ◽  
Fdg Pet ◽  
Primary Breast Cancer ◽  
Whole Body ◽  
Newly Diagnosed ◽  
Breast Cancer Patients ◽  
Initial Staging

Abstract Objectives To compare the diagnostic performance of [18F]FDG PET/MRI, MRI, CT, and bone scintigraphy for the detection of bone metastases in the initial staging of primary breast cancer patients. Material and methods A cohort of 154 therapy-naive patients with newly diagnosed, histopathologically proven breast cancer was enrolled in this study prospectively. All patients underwent a whole-body [18F]FDG PET/MRI, computed tomography (CT) scan, and a bone scintigraphy prior to therapy. All datasets were evaluated regarding the presence of bone metastases. McNemar χ2 test was performed to compare sensitivity and specificity between the modalities. Results Forty-one bone metastases were present in 7/154 patients (4.5%). Both [18F]FDG PET/MRI and MRI alone were able to detect all of the patients with histopathologically proven bone metastases (sensitivity 100%; specificity 100%) and did not miss any of the 41 malignant lesions (sensitivity 100%). CT detected 5/7 patients (sensitivity 71.4%; specificity 98.6%) and 23/41 lesions (sensitivity 56.1%). Bone scintigraphy detected only 2/7 patients (sensitivity 28.6%) and 15/41 lesions (sensitivity 36.6%). Furthermore, CT and scintigraphy led to false-positive findings of bone metastases in 2 patients and in 1 patient, respectively. The sensitivity of PET/MRI and MRI alone was significantly better compared with CT (p < 0.01, difference 43.9%) and bone scintigraphy (p < 0.01, difference 63.4%). Conclusion [18F]FDG PET/MRI and MRI are significantly better than CT or bone scintigraphy for the detection of bone metastases in patients with newly diagnosed breast cancer. Both CT and bone scintigraphy show a substantially limited sensitivity in detection of bone metastases. Key Points • [18F]FDG PET/MRI and MRI alone are significantly superior to CT and bone scintigraphy for the detection of bone metastases in patients with newly diagnosed breast cancer. • Radiation-free whole-body MRI might serve as modality of choice in detection of bone metastases in breast cancer patients.

Sign in / Sign up

Export Citation Format

Share Document